3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Unknown
1
Terminated
1
Suspended
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
23
Neoplasm Metastasis
14
Leukemia, Myeloid, Acute
11
Carcinoma, Renal Cell
10
Neoplasms
8
Kidney Neoplasms
8
Skin Neoplasms
5
Recurrence
5
Leukemia
5
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
5
Ovarian Neoplasms
4
Lymphoma, Non-Hodgkin
4
Colorectal Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Neuroblastoma
3
Lymphoma, Follicular
3
Congenital Abnormalities
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Head and Neck Neoplasms
2
Carcinoma, Merkel Cell
2
Interventions
Cyclophosphamide
24
Mycophenolic Acid
15
fludarabine phosphate
14
fludarabine
13
Whole-Body Irradiation
13
Tacrolimus
12
Rituximab
12
Melphalan
12
Filgrastim
11
Cyclosporine
11
Busulfan
11
Radiotherapy
10
Peripheral Blood Stem Cell Transplantation
10
Antilymphocyte Serum
10
Methotrexate
9
Doxorubicin
9
Gemcitabine
8
Etoposide
8
Brentuximab Vedotin
8
Sirolimus
7
pembrolizumab
6
Vinblastine
6
Nivolumab
6
Methylprednisolone
6
Granulocyte Colony-Stimulating Factor
6
Alemtuzumab
6
Dacarbazine
5
Cytarabine
5
Cord Blood Stem Cell Transplantation
5
Carmustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hodgkin Disease
×
Interleukin-2
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts